IBRX

+ Watchlist + Portfolio

ImmunityBio, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.13
52-Week Range: $1.95 – $12.43
Market Cap: $8.31B
P/E (TTM): —
EPS (TTM): -0.95
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -30.54%
Gross Margin: 99.34%
Operating Margin: -120.41%
Profit Margin: 0.00%
Current Ratio: 5.72
Debt/Equity: —
Total Debt: $1.23B
Free Cash Flow: $-186.56M
Revenue Growth: 93.90%
Earnings Growth: —
Enterprise Value: $9.18B

IBRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$240.00K	$622.00K	$14.74M	$113.29M
Cost of Revenue	$0.00	$0.00	$0.00	$753.00K
Gross Profit	$240.00K	$622.00K	$14.74M	$112.53M
Research & Development	$248.15M	$232.37M	$190.14M	$218.56M
Selling, General & Admin	$102.71M	$129.62M	$168.78M	$150.00M
Operating Expenses	$350.86M	$361.99M	$358.93M	$368.56M
Operating Income	-$350.62M	-$361.36M	-$344.18M	-$256.03M
EBITDA	-$351.88M	-$478.58M	-$264.35M	-$223.56M
Pretax Income	-$417.29M	-$583.89M	-$413.64M	-$351.61M
Income Tax	$34.00K	-$40.00K	$0.00	-$135.00K
Net Income	-$416.57M	-$583.20M	-$413.56M	-$351.40M
Diluted EPS	-1.04	-1.15	-0.62	-0.38
Diluted Shares	399.90M	508.64M	700.44M	919.86M

IBRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$104.64M	$265.45M	$143.43M	$88.33M
Receivables	$1.89M	$3.17M	$2.65M	$42.62M
Inventory	—	$0.00	$8.27M	$910.00K
Current Assets	$140.58M	$294.08M	$184.59M	$314.88M
Total Assets	$362.36M	$504.45M	$382.93M	$501.90M
Current Liabilities	$500.86M	$58.28M	$54.94M	$61.75M
Long-Term Debt	$241.27M	$681.54M	$461.88M	$477.09M
Total Debt	$723.77M	$726.72M	$504.17M	$518.08M
Total Liabilities	$812.18M	$1.09B	$871.06M	$1.00B
Retained Earnings	-$2.38B	-$2.96B	-$3.38B	-$3.73B
Shareholders' Equity	-$447.33M	-$586.99M	-$489.10M	-$500.47M
Working Capital	-$360.28M	$235.80M	$129.64M	$253.12M
Net Debt	$568.53M	$416.08M	$318.45M	$388.76M

IBRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$337.51M	-$366.76M	-$391.24M	-$304.94M
Capital Expenditure	-$99.39M	-$30.58M	-$6.89M	-$4.25M
Free Cash Flow	-$436.90M	-$397.34M	-$398.12M	-$309.19M
Depreciation & Amortisation	$18.26M	$18.51M	$17.55M	$15.53M
Stock-Based Compensation	$40.18M	$49.16M	$34.43M	$36.81M
Investing Cash Flow	$27.30M	-$30.47M	-$12.25M	-$149.80M
Financing Cash Flow	$233.61M	$558.34M	$281.63M	$400.24M
Net Change in Cash	-$76.60M	$161.11M	-$121.85M	-$54.50M

IBRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$16.52M	$26.43M	$32.06M	$38.28M	$44.21M
Cost of Revenue	$58.00K	$136.00K	$177.00K	$382.00K	$238.00K
Gross Profit	$16.46M	$26.29M	$31.88M	$37.90M	$43.97M
Research & Development	$48.23M	$55.24M	$51.23M	$63.86M	$67.99M
Selling, General & Admin	$32.65M	$42.34M	$36.28M	$38.73M	$45.77M
Operating Expenses	$80.89M	$97.57M	$87.51M	$102.59M	$113.76M
Operating Income	-$64.43M	-$71.28M	-$55.63M	-$64.68M	-$69.79M
EBITDA	-$97.21M	-$59.54M	-$35.77M	-$31.04M	-$599.94M
Pretax Income	-$129.90M	-$92.31M	-$67.31M	-$62.09M	-$632.79M
Income Tax	-$234.00K	$269.00K	-$35.00K	-$135.00K	$9.00K
Net Income	-$129.65M	-$92.56M	-$67.25M	-$61.94M	-$632.78M
Diluted EPS	-0.15	-0.10	-0.07	-0.06	-0.62
Diluted Shares	853.16M	888.22M	946.60M	989.68M	1.03B

IBRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$60.66M	$137.66M	$60.24M	$88.33M	$205.19M
Receivables	$17.45M	$22.33M	$33.72M	$42.62M	$43.27M
Inventory	$8.44M	$6.64M	$6.70M	$910.00K	$547.00K
Current Assets	$109.16M	$208.13M	$329.50M	$314.88M	$452.95M
Total Assets	$303.76M	$402.08M	$518.99M	$501.90M	$646.64M
Current Liabilities	$49.20M	$50.64M	$57.13M	$61.75M	$67.95M
Long-Term Debt	$485.72M	$492.08M	$500.80M	$477.09M	$678.39M
Total Debt	$526.27M	$535.32M	$542.25M	$518.08M	$719.16M
Total Liabilities	$894.24M	$971.89M	$1.04B	$1.00B	$1.52B
Retained Earnings	-$3.50B	-$3.60B	-$3.66B	-$3.73B	-$4.36B
Shareholders' Equity	-$591.43M	-$570.75M	-$524.32M	-$500.47M	-$870.01M
Working Capital	$59.96M	$157.49M	$272.36M	$253.12M	$385.00M
Net Debt	$425.06M	$354.43M	$440.56M	$388.76M	$473.19M

IBRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$85.91M	-$79.75M	-$68.91M	-$70.38M	-$75.36M
Capital Expenditure	-$1.12M	-$1.08M	-$775.00K	-$1.27M	-$1.79M
Free Cash Flow	-$87.03M	-$80.83M	-$69.68M	-$71.65M	-$77.15M
Depreciation & Amortisation	$3.83M	$3.88M	$3.95M	$3.87M	$4.38M
Stock-Based Compensation	$9.54M	$9.65M	$8.88M	$8.75M	$8.17M
Investing Cash Flow	$4.13M	-$16.14M	-$181.36M	$43.57M	-$31.65M
Financing Cash Flow	-$982.00K	$172.81M	$173.52M	$54.89M	$223.93M
Dividends Paid	$0.00	—	—	—	—
Net Change in Cash	-$82.76M	$76.92M	-$76.75M	$28.09M	$116.92M

Market Snapshot

About

ImmunityBio is a late-stage biotechnology company developing therapies and vaccines to fight cancer and infectious diseases by amplifying both natural killer cell and T cell responses. The company's lead immunotherapy candidate, Anktiva (N-803), is an IL-15 superagonist designed to activate the body's immune system. ImmunityBio has received FDA approval for Anktiva in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer and is evaluating it in multiple other cancer indications. The company also developed a COVID-19 vaccine and is advancing cell therapy programs through its subsidiary NantKwest.